Literature DB >> 17199602

A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita.

S M Crichlow, N J Mortimer, K E Harman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17199602     DOI: 10.1111/j.1365-2133.2006.07596.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  15 in total

Review 1.  Epidermolysis bullosa acquisita.

Authors:  Rishu Gupta; David T Woodley; Mei Chen
Journal:  Clin Dermatol       Date:  2012 Jan-Feb       Impact factor: 3.541

Review 2.  Epidermolysis bullosa acquisita: autoimmunity to anchoring fibril collagen.

Authors:  Mei Chen; Gene H Kim; Lori Prakash; David T Woodley
Journal:  Autoimmunity       Date:  2011-09-28       Impact factor: 2.815

3.  Rituximab for autoimmune blistering diseases: recent studies, new insights.

Authors:  L Lunardon; A S Payne
Journal:  G Ital Dermatol Venereol       Date:  2012-06       Impact factor: 2.011

Review 4.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

5.  Epidermolysis bullosa acquisita with moderately severe Dysphagia due to esophageal strictures.

Authors:  Jenny Tu; Prasad W Kumarasinghe
Journal:  Indian J Dermatol       Date:  2011-03       Impact factor: 1.494

6.  Rituximab in severe skin diseases: target, disease, and dose.

Authors:  Daniel D Bennett; Maro Ohanian; Christian T Cable
Journal:  Clin Pharmacol       Date:  2010-07-07

7.  Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita.

Authors:  Ralf J Ludwig
Journal:  ISRN Dermatol       Date:  2013-07-15

Review 8.  Autoimmunity against type VII collagen in inflammatory bowel disease.

Authors:  Gheorghe Hundorfean; Markus F Neurath; Cassian Sitaru
Journal:  J Cell Mol Med       Date:  2010-10       Impact factor: 5.310

Review 9.  Epidermolysis bullosa acquisita: current diagnosis and therapy.

Authors:  Christine R Mehren; Robert Gniadecki
Journal:  Dermatol Reports       Date:  2011-11-28

10.  Effectiveness and side effects of anti-CD20 therapy for autoantibody-mediated blistering skin diseases: A comprehensive survey of 71 consecutive patients from the Initial use to 2007.

Authors:  Jennifer D Peterson; Lawrence S Chan
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.